Drugs / Tinodasertib
Tinodasertib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03414450 | Apr 2018 → Feb 2022 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, leukemia, myeloid, accelerated-phase | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05462236 | Apr 2023 → Sep 2024 overdue | colorectal cancer | AUM Biosciences Pte Ltd | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tinodasertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462236 ↗ |
| Known as | AUM-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4211649 ↗ |
| Known as | ETC-1907206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03414450 ↗ |
| Known as | Etc-206 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4211649 ↗ |
| Action | Inhibit | “ETC-1907206 has been designed to block the activity of an enzyme of the body known as Mnk kinase” NCT03414450 ↗ |
| Modality | Small molecule | — CHEMBL4211649 ↗ |
| Route | Oral | “ETC-1907206 administered orally EOD under fasted conditions” NCT03414450 ↗ |